Teze­pelum­ab CAS 1572943-04-4

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1572943-04-4

Name

Teze­pelum­ab

Prop­er­ties

Safe­ty Data

Sym­bol

MSDS Download

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our 

Known Appli­ca­tion

Teze­pelum­ab CAS 1572943-04-4 as add-on main­te­nance ther­a­py for the treat­ment of severe asth­ma in chil­dren 12 years of age and old­er and in adults. This is a mon­o­clon­al anti­body ther­a­py tar­get­ing anti-thymic stro­mal lym­phopoi­etin (TSLP). TSLP is an epithe­lial cytokine that sits at the top of mul­ti­ple inflam­ma­to­ry cas­cades, ini­ti­at­ing aller­gic, eosinophilic, and oth­er types of exag­ger­at­ed immune respons­es asso­ci­at­ed with severe asth­­ma-relat­ed air­way inflammation.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Wat­son Bio Lim­it­ed (https://​www​.wat​son​-bio​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.